Fruquintinib Plus Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
Nat. Med. 2024 Jun 01;[EPub Ahead of Print], F Wang, L Shen, W Guo, T Liu, J Li, S Qin, Y Bai, Z Chen, J Wang, Y Pan, Y Shu, F Zhao, Y Cheng, F Ye, K Gu, T Zhang, H Pan, H Zhong, F Zhou, Y Qin, L Yang, W Mao, Q Li, W Dai, W Li, S Wang, Y Tang, D Ma, X Yin, Y Deng, Y Yuan, M Li, W Hu, D Chen, G Li, Q Liu, P Tan, S Fan, M Shi, W Su, RH XuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.